Molecular Health Unveils New Decision Support Solutions for Clinical Interpretation of Cancer Genome Data at AMP 2016 Annual Meeting
(Thomson Reuters ONE) -
Molecular Health Guide(TM) Workbench Manager for comprehensive, end-to-end
clinical decision support
Molecular Health Guide(TM) Clinical Annotation Service for variant analysis and
interpretation
BOSTON and HEIDELBERG, Germany, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Molecular
Health, a leader in decision support technology for precision medicine, today
announced the launch of its next-generation clinical decision support solutions,
Molecular Health Guide(TM) Workbench Manager and Molecular Health
Guide(TM) Clinical Annotation Service. These services are based on the
Company's proprietary cloud-based software platform for the automated analysis,
clinical interpretation, and reporting of genetic alterations from next-
generation sequencing (NGS) performed by laboratories and hospitals. Molecular
Health will be showcasing the new Molecular Health Guide(TM) offerings,
initially provided in oncology, at Booth #1805 during the Association for
Molecular Pathology (AMP) 2016 Annual Meeting taking place November 10-12 at the
Charlotte Convention Center in North Carolina.
These new clinical decision support products are based on Molecular Health's
Dataome(TM) technology, which focuses on the capture, integration, and analysis
of molecular outcomes data from patients that are mapped to expert-curated,
peer-reviewed, published biomedical literature. The curated databases include
clinical variant interpretations (CVIs) that are created by a rigorous process
that includes expert physician review.
Molecular Health Guide(TM) Workbench Manager delivers a comprehensive clinical
decision support service, from bioinformatics analysis of the NGS data from a
patient's tumor to the generation of a custom report. Based upon the
identification of reportable variants, Workbench Manager generates a summary of
potentially effective treatment options, potentially ineffective treatment
options, and treatment options that may pose a higher risk of adverse
reactions. It also provides a matching tool for clinical trials. Workbench
Manager enables physicians and laboratories to reduce the time-consuming, cost-
intensive and error-prone process of manual variant interpretation by providing
clinical annotations and interpretations reviewed by expert molecular
pathologists and oncologists. Workbench Manager features a rich, interactive
user interface and digital workflow for those who want to create a high-quality
tailored report available in minutes.
Molecular Health Guide(TM) Clinical Annotation Service powers the automated
delivery of clinically-reviewed annotations for actionable variants. Within
minutes, Clinical Annotation Service delivers client customized clinically-
relevant data, including: clinical variant narratives, evidence-based treatment
options, matching trials, and other supplemental data such as drug descriptions
and relevant drug-drug interactions. The technology is highly scalable and
easily integrated into existing workflows, pipeline management, and reporting
systems for use by high-throughput laboratories and other high-volume customers.
Les Paul, MD, MS, Chief Medical Officer and U.S. CEO, Molecular Health,
commented, "Molecular Health Guide(TM) clinical decision support solutions help
molecular pathologists and oncologists to more effectively manage molecular
information from Next-Generation Sequencing of patients' tumors including the
identification of potentially effective or potentially ineffective treatment and
relevant clinical trials. We have designed these offerings to strategically
address the needs of oncologists and pathologists as well as large laboratory,
hospital, and research customers."
Friedrich von Bohlen, Chief Executive Officer, Molecular Health, commented,
"Molecular Health is the leading precision medicine and clinical decision
support option for customers who want access to make more informed treatment
decisions. We developed both Molecular Health Guide(TM) offerings based on the
valuable input of the medical community and now we have a product that is primed
to improve patient care and outcomes by empowering the medical community with
access to real-time solutions which leverage the world's healthcare data. The
breadth and quality of our contributions to the medical community are
exemplified with this product launch and our recent Clinical Laboratory
Improvement Amendments (CLIA) certification and College of American Pathologists
(CAP) accreditation for bioinformatics analysis, variant annotation and
interpretation. This launch executes on our mission to power the future of
precision medicine."
Molecular Health GmbH is certified according to DIN EN ISO 13485 for the design,
development and manufacture of software systems for the integrated analysis of
clinical and genomic patient data to support treatment decisions and provision
of related services. In addition, Molecular Health is Clinical Laboratory
Improvement Amendments (CLIA) certified and accredited by the College of
American Pathologists (CAP) for bioinformatics analysis, variant annotation and
interpretation. This allows Molecular Health to provide its bioinformatics
analysis services to clinical laboratories in the United States that are also
accredited.
In the European Union, Molecular Health Guide(TM) is registered as an In Vitro
Diagnostic (IVD) device.
About Molecular Health
Molecular Health is a leading precision medicine informatics company that
leverages its proprietary cloud-based Dataome(TM) technology platform to provide
a comprehensive and disruptive healthcare decision engine. The
Dataome(TM) technology platform is the culmination of carefully curated and
medically-reviewed information from millions of scientific and medical
publications together with data from globally available databases of clinical
and molecular information. The platform is regularly updated and curated by
biomedical experts along strict processes, and has robust and expanding IP
protection. Dataome(TM) technology powers the Company's Molecular Health
Guide(TM) service offerings.
Molecular Health GmbH is located in Heidelberg, Germany and its subsidiary,
Molecular Health, Inc., is located in Boston, Massachusetts, USA.
To learn more, please visit: www.molecularhealth.com.
Investors
Nick Laudico
The Ruth Group
(646) 536-7030
nlaudico(at)theruthgroup.com
Media
Kirsten Thomas / Chris Hippolyte
The Ruth Group
+1 508-280-6592 / +1 646-536-7023
kthomas(at)theruthgroup.com / chippolyte(at)theruthgroup.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Molecular Health via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2016 - 14:00 Uhr
Sprache: Deutsch
News-ID 505350
Anzahl Zeichen: 7596
contact information:
Town:
The Woodlands
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Molecular Health Unveils New Decision Support Solutions for Clinical Interpretation of Cancer Genome Data at AMP 2016 Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Molecular Health (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
